Clinical Trials
10 trialsNCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT00795002 2018-08-07
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01349972 2017-07-31
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098371 2016-10-24
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00407966 2015-08-04
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00634244 2015-07-07
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00464633 2013-02-12
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Sanofi
Phase 2 Completed
NCT00003039 2013-02-05
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003620 2013-01-17
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed